PureBMC® is SupraPhysiologic BMC

Galvanizing the power of progenitor stem cells

PureBMC® is now processed in a single GenesisCS Concentrating Device, producing supraphysiologic levels of progenitor stem cells consisting of hematopoietic stem cells, mesenchymal stem cells and total nucleated cells. The complexity of processing has been eliminated and the power of the PureBMC® biologic has been amplified. PureBMC® currently leads all point of care bone marrow concentrating systems in performance outcomes, and now go further with supraphysiologic procurement and quiescent cell collection, now achieved with the ASPIRE™ Bone Marrow Harvesting System.

Image is not available
Image is not available

A purified progenitor biologic

Derived from parenchymal red bone marrow

__________________________________________________________________________________________________________________

Slider

PureBMC® is now processed in a single GenesisCS Concentrating Device, producing supraphysiologic levels of progenitor stem cells consisting of hematopoietic stem cells, mesenchymal stem cells and total nucleated cells.  The complexity of processing has been eliminated and the power of the PureBMC® biologic has been amplified.  PureBMC® currently leads all point of care bone marrow concentrating systems in performance outcomes, and now go further with supraphysiologic procurement and quiescent cell collection, now achieved with the ASPIRE™ Bone Marrow Harvesting System.


 

PureBMC® is making a real difference

Features that truly improve outcomes

Extracellular hemoglobin is known to trigger specific pathologies associated with adverse clinical outcomes. PureBMC® collects and processes a pure sample of bone marrow with minimal hemolysis by virtue of its unique collection and processing technique.

Material mediated coagulation studies show that there is no statistical significant difference between the clot time of plasma and the PureBMC® concentrating device. This allows bone marrow to processed without heparin, ultimately preserving functionality of stem cells, platelets and growth factors.

PureBMC® has a progenitor cell viability of 97%, partially due to its gentle processing technique and quiescent aspiration attained with the ASPIRE™ bone marrow needle. This is the highest independently rated cell viability of any point of care bone marrow concentrating system.

Image is not available

LESS TISSUE ACTIVATION

LESS CLOTTING

LESS FREE HEMOGLOBIN

_________________________________________________________________________________________________________________________________________________

Slider

 PureBMC®

Independent Performance Evaluation

2017

 

PureBMC® volume (7.5mL)

 
CD34+ yield%
88%
CFU-f (MSC) yield % 88%
TNC yield % 80%
CD34+ concentration x baseline
7.3
CFU-f (MSC) concentration x baseline

7.4

TNC concentration x baseline
6.4
Platelet concentration x baseline
6.4
PDGF AB concentration x baseline 4.4
Call customer support for more information on data results

 

Give us a Call

239-481-7725

Send us a Message

Support@emcyte.com

Visit our Location

4331 Veronica S. Shoemaker Blvd., Suite 4

Fort Myers, FL 33916